Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S. Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully ...

Structure Therapeutics (GPCR) has been capturing some attention lately, especially after its shares posted gains of more than 40% over the past month. Investors are curious whether this momentum can ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

Through an international collaboration, scientists at St. Jude Children’s Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Structure Therapeutics (GPCR) has drawn attention after recent share price swings, including a month return of a 27.7% decline and a past 3 months gain of 80.8%, prompting investors to reassess its ...

「Gタンパク質共役型受容体（GPCR）」は、がん性疼痛や気管支ぜんそくなど多くの疾患に関わるタンパク質です。これまでGPCRを標的に多くの薬が開発されてきましたが、最近、限界を迎え、従来の方法では活性の高い薬が見つかりにくくなっています。